U.S. Markets close in 1 hr 13 mins

Aligos Therapeutics, Inc. (ALGS)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
13.57-1.19 (-8.03%)
As of 2:45PM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close14.76
Open14.53
Bid13.60 x 1200
Ask13.50 x 1000
Day's Range12.82 - 14.93
52 Week Range12.82 - 14.93
Volume563,144
Avg. VolumeN/A
Market Cap500.784M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Barrons.com

    Hearing-Aid Maker Eargo Soars 87% in Its First Trading Day

    Eargo is one of several companies go public Friday. Praxis Precision Medicines, Tarsus Pharmaceuticals, and Aligos Therapeutics are also on tap to commence trading.

  • Barrons.com

    There’s an IPO Party in Biotech. Praxis Precision Led Friday’s Slate With a 62% Pop.

    (PRAX) which saw its shares rise 62%, led a flurry of biotech companies making their public market debuts Friday. Biotech has emerged as one of the busiest sectors of the IPO market. Including the four companies launching IPOs Friday, 12 biotechs have tapped the equity markets so far this month.

  • MarketWatch

    Aligos Therapeutics stock rallies out of the gate, then pulls back

    Shares of Aligos Therapeutics Inc. rallied out of the gate Friday, as they opened 16% above the initial public offering price. The stock's first trade on the Nasdaq was at $17.40 at 1:33 p.m. Eastern for 485,960 shares. The IPO was priced late Thursday at $15 a share, in the middle of the expected range of between $14 and $16 a share. The California-based biopharmaceutical company focused on viral and liver disease treatments raised $150 million in the IPO, and the pricing valued that company at about $540.8 million. The stock has pulled back since the opening, as it hit an intraday low of $13.63, or 9.1% below the IPO price, before bounding to be up 0.6% in afternoon trading. The company has gone public at a time of strong investor demand for IPOs, as the Renaissance IPO ETF has soared 32.6% over the past three months, while the iShares Nasdaq Biotechnology ETF has slipped 0.8% and the S&P 500 has gained 9.0%.